István T. Vályi-nagy - Infectious Diseases

Author Information

István T. Vályi-Nagy is affiliated with the Central Hospital of Southern Pest-National Institute for Hematology and Infectious Diseases in Budapest, Hungary. As a researcher deeply involved in the study of infectious diseases, he has contributed significantly to the understanding of conditions such as COVID-19 and various hematological disorders. His work is well-recognized within the scientific community, particularly in the fields of virology and immunology.

Research Contributions

István T. Vályi-Nagy has made substantial contributions to the field of infectious diseases and hematology, with a focus on the pathology and treatment of COVID-19. His research encompasses the prognostic biomarkers for severe COVID-19 outcomes, the immune response to SARS-CoV-2 vaccinations, and the therapeutic strategies for multiple myeloma. Notably, his studies have explored the enzyme activity of dipeptidyl peptidase-4 as a biomarker for COVID-19 severity and mortality, as well as the efficacy of venetoclax therapy in multiple myeloma cases.

Aliases

István T. Vályi-Nagy is also known by several aliases, including Istvan Valyi-nagy, I Valyi-nagy, I Vályi-nagy, I. Valyi-nagy, and István Vályi-nagy. These variations in his name appear across different publications and databases.

Publication and Citation Metrics

Metric	Value
Total Citation Count	1201
H-Index	20
Total Paper Count	104

Publications:

Decreased circulating dipeptidyl peptidase-4 enzyme activity is prognostic for severe outcomes in COVID-19 inpatients

DOI: 10.2217/bmm-2021-0717

Year: 2022

COVID-19: autoimmunity, multisystemic inflammation and autoimmune rheumatic patients

DOI: 10.1017/erm.2022.10

Year: 2022

Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers

DOI: 10.3389/pore.2022.1610276

Year: 2022

Associations between the von Willebrand Factor—ADAMTS13 Axis, Complement Activation, and COVID-19 Severity and Mortality

DOI: 10.1055/s-0041-1740182

Year: 2022

Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy

DOI: 10.3390/vaccines10040539

Year: 2022

Lasting Complete Clinical Response of a Recurring Cutaneous Squamous Cell Carcinoma With MEK Mutation and PIK3CA Amplification Achieved by Dual Trametinib and Metformin Therapy.

DOI: 10.1200/po.21.00344

Year: 2022

Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia

DOI: 10.1371/journal.pone.0253386

Year: 2021

Personalized First-Line Treatment of Metastatic Pancreatic Neuroendocrine Carcinoma Facilitated by Liquid Biopsy and Computational Decision Support

DOI: 10.3390/diagnostics11101850

Year: 2021

Soluble Dipeptidyl-Peptidase 4 (sDPP4) Serum Activity Is Associated With the Severity of COVID-19 Disease and is a Strong Prognostic Biomarker of Mortality

DOI: 10.2139/ssrn.3864903

Year: 2021

P-087: Real world efficacy and safety of venetoclax in t(11;14) multiple myeloma in Hungary

DOI: 10.1016/s2152-2650(21)02221-7

Year: 2021

Why is Artemisinin Important in Malaria Treatment?

Who Should Not Receive the DTaP Vaccine?

How Can Microcephaly Be Diagnosed?

What are the Limitations of PCR Tests?

What is Symptomatic Relief?

How do ACTs Work?

Can Monogamous Relationships Prevent Non-Sexual Infectious Diseases?

How Does Parasite DNA Contribute to Drug Resistance?

What are the Side Effects?

Are There Metabolic Pathway Differences Between Pathogens and Hosts?

Partnered Content Networks

Relevant Topics